Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Operating Income · Q2 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q2 FY2026 operating income was -CA$15.57M, compared with -CA$3.35M a year earlier. Trailing-twelve-month operating income was -CA$31.43M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate of CA$0 (+100.0%) for the fiscal year ending Sep 2026, a step up from the -393.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$15.57M-125.5% QoQ
Last fiscal yearSep 2025
-CA$13.94M-393.8% YoY
LTMMar 2026
-CA$31.43M-468.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-364.5%+100.0%+464.5 pp
1 year-393.8%+100.0%+493.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

CAD · from the income statement

Latest · FY2025
(13.94M) CAD
Year-over-year change
-393.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Operating Income figures are available to compare.

Income Statement

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.31M12.18M5M1.18M11.08M
Selling, General & Admin2.31M2.55M2.2M1.45M2.57M
Operating Expenses8.62M14.98M7.39M2.82M13.94M
Depreciation & Amortization8.62M6.04K72.45K73.36K76.87K
EBITDA(27.64K)(14.96M)(7.3M)(2.73M)(12.15M)
EBITDA Margin—————
Operating Income(8.62M)(14.98M)(7.39M)(2.82M)(13.94M)
Operating Margin—————
Interest Income00030.13K1.52M
Interest Expense00000
Other Income / Expenses(27.64K)10.15K14.19K20.82K1.71M
Income Before Tax(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Net Margin—————
EPS (Basic)(4.74)(6.15)(1.98)(0.65)(1.78)
EPS (Diluted)(4.74)(6.15)(1.98)(0.65)(1.78)
Weighted Avg Shares1.79M2.47M3.72M4.31M6.88M
Weighted Avg Shares (Diluted)1.79M2.47M3.72M4.31M6.88M

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.